PHA Pharmagest Interactive SA

Equasens: RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED TO THE ORDINARY ANNUAL SHAREHOLDERS' MEETING OF 27 JUNE 2024

Equasens: RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED TO THE ORDINARY ANNUAL SHAREHOLDERS' MEETING OF 27 JUNE 2024

        

Villers-lès-Nancy, 5 July 2024 - 6:00 p.m. (CET)

PRESS RELEASE

RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED

TO THE ORDINARY ANNUAL SHAREHOLDERS' MEETING

OF 27 JUNE 2024

Number of shares comprising the share capital: 15,174,125

Number of shares with voting rights: 15,031,080

Number of shares with voting rights possessed by shareholders presents or represented or having voted by mail: 13,070,268

That means a quorum of 86.95% of the 15,031,080 shares with voting rights: the Ordinary Annual General Meeting was able to deliberate.

The Ordinary Annual General Meeting was held on Thursday, 27 June 2024 at 5:30 p.m. at the Company’s headquarters and approved the separate parent company and consolidated financial statements for the 2023 financial year. The results of the votes on the resolutions proposed at this meeting by the Board of Directors were as follows:

Resolutions  



Results of the votes



 
  • RESOLUTION ONE
Approval of the annual financial statements		Resolution adopted by:
  • 13,068,136 votes in favour
  • 0 vote against
  • 2,132 abstentions
  • RESOLUTION TWO
Discharge of directors and discharge of the Statutory Auditors for the performance of their engagement		Resolution adopted by:
  • 12,777,518 votes in favour
  • 290,512 votes against
  • 2,238 abstentions
  • RESOLUTION THREE

    Approval of the consolidated financial statements
Resolution adopted by:
  • 13,068,136 votes in favour
  • 0 vote against
  • 2,132 abstentions
  • RESOLUTION FOUR
Appropriation of earnings, setting the dividend		Resolution adopted by:
  • 13,070,236 votes in favour
  • 0 vote against
  • 32 abstentions
  • RESOLUTION FIVE
Agreements and commitments governed by Articles L. 225-38 of the French Commercial Code		Resolution adopted by (*):
  • 13,023,724 votes in favour
  • 46,492 votes against
  • 32 abstentions
  • RESOLUTION SIX
Renewal of Ms. Sophie MAYEUX's term of office as Director		Resolution adopted by:
  • 10,650,758 votes in favour
  • 2,419,478 votes against
  • 32 abstentions
  • RESOLUTION SEVEN
Appointment of BM&A as Sustainability Auditor		Resolution adopted by:
  • 13,070,236 votes in favour
  • 0 vote against
  • 32 abstentions
  • RESOLUTION EIGHT
Approval of the information on the compensation of corporate officers paid in or granted for fiscal 2023 and mentioned in Article L. 22-10-9 of the French Commercial Code		Resolution adopted by:
  • 12,189,192 votes in favour
  • 881,044 votes against
  • 32 abstentions
  • RESOLUTION NINE
Approval of the components of compensation paid in 2023 to Mr. Thierry CHAPUSOT, Chairman of the Board of Directors		Resolution adopted by:
  • 13,006,839 votes in favour
  • 63,397 votes against
  • 32 abstentions
  • RESOLUTION TEN
Approval of the components of compensation paid in 2023 to Mr. Dominique PAUTRAT, Chief Executive Officer until 22/04/2022		Resolution adopted by:
  • 13,070,236 votes in favour
  • 0 vote against
  • 32 abstentions
  • RESOLUTION ELEVEN
Approval of the components of compensation paid in 2023 to Mr. Denis SUPPLISSON, Chief Executive Officer		Resolution adopted by:
  • 10,519,109 votes in favour
  • 2,551,127 votes against
  • 32 abstentions
  • RESOLUTION TWELVE
Approval of the components of compensation paid in 2023 to Mr. Grégoire DE ROTALIER, Deputy CEO		Resolution adopted by:
  • 10,468,599 votes in favour
  • 2,601,637 votes against
  • 32 abstentions
  • RESOLUTION THIRTEEN
Approval of the compensation policy for Mr. Thierry CHAPUSOT, Chairman of the Board of Directors, for 2024		Resolution adopted by:
  • 13,006,839 votes in favour
  • 63,397 votes against
  • 32 abstentions
  • RESOLUTION FOURTEEN
Approval of the compensation policy for Mr. Denis SUPPLISSON, Chief Executive Officer, for 2024		Resolution adopted by:
  • 10,473,009 votes in favour
  • 2,356,603 votes against
  • 240,656 abstentions
  • RESOLUTION FIFTEEN
Approval of the compensation policy for Mr. Grégoire de ROTALIER, Deputy Chief Executive Officer, for 2024		Resolution adopted by:
  • 10,472,921 votes in favour
  • 2,356,691 votes against
  • 240,656 abstentions
  • RESOLUTION SIXTEEN
Approval of the compensation policy for Mr. Damien VALICON, Deputy CEO (non-Board member), as from 01/04/2024		Resolution adopted by:
  • 10,462,222 votes in favour
  • 2,367,390 votes against
  • 240,656 abstentions
  • RESOLUTION SEVENTEEN
Approval of the compensation policy for Directors		Resolution adopted by:
  • 12,985,338 votes in favour
  • 63,397 votes against
  • 21,533 abstentions
  • RESOLUTION EIGHTEEN
Setting total annual compensation for Directors for 2024		Resolution adopted by:
  • 12,985,338 votes in favour
  • 63,397 votes against
  • 21,533 abstentions
  • RESOLUTION NINETEEN
Authorisation by the Company to repurchase its own shares		Resolution adopted by:
  • 10,931,253 votes in favour
  • 2,139,015 votes against
  • 0 abstention
  • RESOLUTION TWENTY
Powers for formalities		Resolution adopted by:
  • 13,070,236 votes in favour
  • 0 vote against
  • 32 abstentions

(*) After deduction of excluded voting rights

Financial Calendar:

  • Publication of H1 2024 Revenue: 2 August 2024 (after French market closure).



About

With more than 1,300 employees, Equasens Group is today a key player in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centres) in both primary and secondary care sectors.

With operations in France, Germany, Great Britain, Belgium, Ireland, Italy, and Luxembourg, Equasens Group today brings together healthcare professionals within a unique ecosystem in France and Europe benefiting people by making available the very best of technology.

Listed on Euronext Paris™ - Compartment B

Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable

Included in the Euronext Tech Leaders segment and the European Rising Tech label

Eligible for the Deferred Settlement Service (“Service à Règlement Différé” - SRD) and equity savings accounts invested in small and mid caps (PEA-PME)

ISIN: FR 0012882389 – Ticker Code: EQS

Get all the news about the Equasens Group and on

CONTACTS

Analyst and Investor Relations:

Chief Administrative and Financial Officer: Frédérique SCHMIDT

Tel. +33 (0)3 83 15 90 67 -

Media Relations:

FIN’EXTENSO - Isabelle APRILE

Tel. +33 (0)6 17 38 61 78 –

Attachment



EN
05/07/2024

Underlying

PHAPharmagest Interactive SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pharmagest Interactive SA

 PRESS RELEASE
Free
PHA Pharmagest Inte...

EQUASENS : Digipharmacie obtient l’immatriculation officielle en tant ...

EQUASENS : Digipharmacie obtient l’immatriculation officielle en tant que Plateforme de Dématérialisation Partenaire (PDP) Villers-lès-Nancy, le 21 novembre 2024 – 18h00 (CET)COMMUNIQUE DE PRESSE Digipharmacie obtient l’immatriculation officielle en tant que Plateforme de Dématérialisation Partenaire (PDP) (Euronext Paris™ - Compartiment B - FR 0012882389 –EQS), leader des solutions numériques pour les professionnels de santé, annonce l’immatriculation officielle de sa filiale Digipharmacie en tant que Plateforme de Dématérialisation Partenaire (PDP) par la Direction Générale des Finance...

November 21, 2024 1 EN
 PRESS RELEASE
Free
PHA Pharmagest Inte...

EQUASENS : Intelligence artificielle : Equasens et Posos transforment ...

EQUASENS : Intelligence artificielle : Equasens et Posos transforment la dispensation pharmaceutique Villers-lès-Nancy, le 20 novembre 2024 – 18h00 (CET)COMMUNIQUE DE PRESSE Le Groupe Equasens et Posos s’associent pour transformer la dispensation en pharmacie grâce à une intelligence artificielle innovante (Euronext Paris™ - Compartiment B - FR 0012882389 –EQS), acteur majeur du numérique en santé, et Posos, medtech spécialisée en intelligence artificielle médicale, annoncent un partenariat stratégique visant à automatiser et sécuriser les étapes clés de la dispensation en pharmacie. C...

November 20, 2024 1 EN
Arnaud Riverain
  • Arnaud Riverain
PHA Pharmagest Inte...

EQUASENS (EQS) - CA T3 : Du mieux... / Achat - Obj. 74 € - Pot. +48%

CA T3 en ligne à 50,3 M€ +0,3% (-3% à périmètre constant) Pharmagest +3,2% : 38 M€ (37,9 M€ attendus) / -1,5% pc Axigate Link -2,7% à 7,2 M€ (7,5 M€ attendus) / -1,1% pc E-Connect 2,8 M€ -23,2% (2,9 M€ attendus) Medical Solutions 1,8 M€ -1,2% en ligne / -2,4% pc CA 9 mois 158,2 M€ -2,8% (-4,9% périmètre constant)

PHA PHARMAGEST INTERACTIVE SA
11/08/24 November 8, 2024 4 FR
 PRESS RELEASE
Free
PHA Pharmagest Inte...

Equasens: 2024 nine-month revenue: €158.2 million - Return to growth i...

Equasens: 2024 nine-month revenue: €158.2 million - Return to growth in Q3 (+0.3%) Villers-lès-Nancy, 7 November 2024 - 6:00 p.m. (CET) PRESS RELEASE 2024 nine-month revenue: €158.2 million                 Return to growth in Q3 (+0.3%) Revenue (€m) 2023Reported basis 2024Reported basis Change /Reported basis - Ségur2024 +Ségur2023 - External Growth   Change /Like-for-like basis Q1 56.2 53.3 -2.9 -5.2% 0.3 1.4 2.0 -3.8 -6.7% Q2 56.4 54.7 -1.7 -3.0% 0.3 1.2 1.7 -2.6 -4.6% Q3 50.1 50.2 0.1 0.3% 0.2 0.3 1.8 -1.5 -3.0% Total 162....

November 7, 2024 1 EN
 PRESS RELEASE
Free
PHA Pharmagest Inte...

EQUASENS : Chiffre d’affaires au 30 septembre 2024 à 158,2 M€ - Retour...

EQUASENS : Chiffre d’affaires au 30 septembre 2024 à 158,2 M€ - Retour de la croissance sur le T3 (+0,3%) Villers-lès-Nancy, le 7 novembre 2024 - 18h00 (CET) COMMUNIQUE DE PRESSE Chiffre d’affaires au 30 septembre 2024 à 158,2 M€                  Retour de la croissance sur le T3 (+0,3%) CA (M€) Publié 2023 Publié 2024 Variation/publié - Ségur 2024 + Ségur 2023 - CroissanceExterne Variation/périmètre comparable T1 56,2 53,3 -2,9 -5,2% 0,3 1,4 2,0 -3,8 -6,7% T2 56,4 54,7 -1,7 -3,0% 0,3 1,2 1,7 -2,6 -4,6% T3 50,1 50,2 0,1 0,3% 0,2...

November 7, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch